CA2090404A1 - Nonaqueous fluorinated drug delivery vehicle suspensions - Google Patents

Nonaqueous fluorinated drug delivery vehicle suspensions

Info

Publication number
CA2090404A1
CA2090404A1 CA002090404A CA2090404A CA2090404A1 CA 2090404 A1 CA2090404 A1 CA 2090404A1 CA 002090404 A CA002090404 A CA 002090404A CA 2090404 A CA2090404 A CA 2090404A CA 2090404 A1 CA2090404 A1 CA 2090404A1
Authority
CA
Canada
Prior art keywords
nonaqueous
drug delivery
delivery vehicle
pharmaceutical compositions
liquid carriers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002090404A
Other languages
French (fr)
Other versions
CA2090404C (en
Inventor
David L. Meadows
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
David L. Meadows
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by David L. Meadows, Allergan, Inc. filed Critical David L. Meadows
Publication of CA2090404A1 publication Critical patent/CA2090404A1/en
Application granted granted Critical
Publication of CA2090404C publication Critical patent/CA2090404C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Abstract

Nonaqueous pharmaceutical compositions for use in aqueous physiological systems are disclosed comprising drug deliv-ery vehicles suspended in nonaqueous perfluorocarbon or fluorinated silicone liquid carriers. The suspended drug delivery vehi-cles may be water labile or water stable and incorporate therapeutic or diagnostic compounds which remain stable and pharma-ceutically effective for extended periods. The pharmaceutical compositions possess extended shelf-lives and do not leach the incorporated therapeutic or diagnostic compounds into the liquid carriers making them well suited for multi-dose packaging and administration.
CA002090404A 1990-09-27 1991-09-10 Nonaqueous fluorinated drug delivery vehicle suspensions Expired - Fee Related CA2090404C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/588,697 US5173298A (en) 1990-09-27 1990-09-27 Nonaqueous fluorinated drug delivery vehicle suspensions
US588,697 1990-09-27
PCT/US1991/006596 WO1992005770A1 (en) 1990-09-27 1991-09-10 Drug delivery vehicles suspended in nonaqueous perfluorinated carrier

Publications (2)

Publication Number Publication Date
CA2090404A1 true CA2090404A1 (en) 1992-03-28
CA2090404C CA2090404C (en) 2001-11-20

Family

ID=24354930

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002090404A Expired - Fee Related CA2090404C (en) 1990-09-27 1991-09-10 Nonaqueous fluorinated drug delivery vehicle suspensions

Country Status (16)

Country Link
US (1) US5173298A (en)
EP (1) EP0550615B1 (en)
JP (1) JP3253072B2 (en)
KR (1) KR100195760B1 (en)
AT (1) ATE125696T1 (en)
AU (1) AU656919B2 (en)
CA (1) CA2090404C (en)
DE (1) DE69111821T2 (en)
ES (1) ES2075468T3 (en)
IE (1) IE69016B1 (en)
IL (1) IL99290A (en)
NZ (1) NZ239558A (en)
PT (1) PT99108B (en)
TW (1) TW224428B (en)
WO (1) WO1992005770A1 (en)
ZA (1) ZA916770B (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048857A (en) * 1989-10-17 2000-04-11 Ellinwood, Jr.; Everett H. Dosing method of administering medicaments via inhalation administration
US5660851A (en) * 1989-12-26 1997-08-26 Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem Ocular inserts
IL97065A (en) * 1990-02-02 1994-01-25 Fisons Plc Aerosol propellant compositions
JPH05507683A (en) * 1990-04-27 1993-11-04 アラーガン、インコーポレイテッド Polymer drug delivery system
DE4201079C3 (en) * 1992-01-17 1997-09-11 Gramer Eugen Combination preparations for lowering intraocular pressure
WO1993018748A1 (en) * 1992-03-19 1993-09-30 Allergan, Inc. Compositions comprising a drug delivery vehicle suspended in a nonaqueous fluorinated liquid
ATE220327T1 (en) 1992-09-29 2002-07-15 Inhale Therapeutic Syst PULMONARY RELEASE OF ACTIVE FRAGMENTS OF THE PARATHORMONE
US5336487A (en) * 1993-03-05 1994-08-09 Refojo Miguel F Method of treating eye disorders with silicon/fluorosilicone copolymer oil
CA2184814A1 (en) 1994-03-04 1995-09-14 Allan S. Hoffman Block and graft copolymers and methods relating thereto
DE4414755C2 (en) * 1994-04-27 2000-11-16 Lohmann Therapie Syst Lts Collagen preparation for the controlled delivery of active ingredients, processes and use
US5661029A (en) * 1994-05-12 1997-08-26 Biomed Biological culture growth and observation device
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US5503869A (en) * 1994-10-21 1996-04-02 Glaxo Wellcome Inc. Process for forming medicament carrier for dry powder inhalator
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
JPH10510198A (en) * 1995-05-12 1998-10-06 ジェネンテク・インコーポレイテッド Coarse spray delivery of functional biological materials
US5667809A (en) * 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
US5874469A (en) * 1996-01-05 1999-02-23 Alcon Laboratories, Inc. Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs
US5861175A (en) * 1996-03-15 1999-01-19 Alliance Pharmaceutical Corp. Use of fluorocarbons for diagnosis and treatment of articular disorders
EP1616563A3 (en) * 1996-05-24 2006-01-25 Angiotech Pharmaceuticals, Inc. Perivascular administration of anti-angiogenic factors for treating or preventing vascular diseases
US20030077317A1 (en) * 1996-06-25 2003-04-24 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients
US5955096A (en) * 1996-06-25 1999-09-21 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients
US6090800A (en) * 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
GB9816724D0 (en) * 1998-08-01 1998-09-30 Boots Co Plc Therapeutic agents
EP1162956B8 (en) * 1999-02-23 2005-08-10 Angiotech International AG Compositions and methods for improving integrity of compromised body passageways and cavities
CA2382133C (en) 2000-05-10 2010-11-23 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US20040076682A1 (en) * 2001-02-15 2004-04-22 Toshiyuki Kohzaki Novel ophthalmic compositions
ES2364636T3 (en) 2001-12-19 2011-09-08 Novartis Ag PULMONARY ADMINISTRATION OF AMINOGLUCOSIDS.
WO2004078778A2 (en) 2003-03-03 2004-09-16 Dyax Corp. PEPTIDES THAT SPECIFICALLY BIND HGF RECEPTOR (cMet) AND USES THEREOF
US20050118124A1 (en) * 2003-12-01 2005-06-02 Reinhart Gale M. Compositions for treating keratinous surfaces
MXPA06014425A (en) * 2004-06-08 2007-05-23 Ocularis Pharma Inc Hydrophobic ophthalmic compositions and methods of use.
US8153435B1 (en) * 2005-03-30 2012-04-10 Tracer Detection Technology Corp. Methods and articles for identifying objects using encapsulated perfluorocarbon tracers
US20070219127A1 (en) * 2006-03-20 2007-09-20 Walt John G Cyclosporin a compositions
JP2010539245A (en) 2007-09-14 2010-12-16 日東電工株式会社 Drug carrier
US9057712B1 (en) 2011-10-27 2015-06-16 Copilot Ventures Fund Iii Llc Methods of delivery of encapsulated perfluorocarbon taggants

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3911138B1 (en) * 1973-02-26 1996-10-29 Childrens Hosp Medical Center Artificial blood and method for supporting oxygen transport in animals
US4105798A (en) * 1976-07-19 1978-08-08 Sun Ventures, Inc. Perfluoro polycyclic compounds for use as synthetic blood and perfusion media
US4115544A (en) * 1976-08-18 1978-09-19 Alza Corporation Ocular system made of bioerodible esters having linear ether
EP0031353B1 (en) * 1979-06-25 1984-08-08 Suntech, Inc. Use of perfluorocarbon as burn treatment
US4452818A (en) * 1982-03-19 1984-06-05 Haidt Sterling J Extraocular method of treating the eye with liquid perfluorocarbons
GR78151B (en) * 1982-04-05 1984-09-26 Alcon Lab Inc
US4649047A (en) * 1985-03-19 1987-03-10 University Of Georgia Research Foundation, Inc. Ophthalmic treatment by topical administration of cyclosporin
US4879304A (en) * 1987-05-01 1989-11-07 Angelini Pharmaceuticals Ltd. Ophthalmic compositions and process for preparing
US4865846A (en) * 1988-06-03 1989-09-12 Kaufman Herbert E Drug delivery system
US4882150A (en) * 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
FR2643572A1 (en) * 1988-12-22 1990-08-31 Rhone Poulenc Chimie METHOD FOR ENCAPSULATING PARTICLES BY FILMING USING A THERMOPLASTIC SILICONE COPOLYMER

Also Published As

Publication number Publication date
ES2075468T3 (en) 1995-10-01
JPH06501258A (en) 1994-02-10
IE69016B1 (en) 1996-07-24
DE69111821T2 (en) 1995-12-14
US5173298A (en) 1992-12-22
ATE125696T1 (en) 1995-08-15
IL99290A (en) 1996-09-12
IL99290A0 (en) 1992-07-15
PT99108B (en) 1999-02-26
CA2090404C (en) 2001-11-20
TW224428B (en) 1994-06-01
JP3253072B2 (en) 2002-02-04
AU8644291A (en) 1992-04-28
EP0550615B1 (en) 1995-08-02
DE69111821D1 (en) 1995-09-07
KR100195760B1 (en) 1999-06-15
EP0550615A1 (en) 1993-07-14
AU656919B2 (en) 1995-02-23
PT99108A (en) 1993-11-30
WO1992005770A1 (en) 1992-04-16
ZA916770B (en) 1992-04-29
IE913379A1 (en) 1992-04-08
NZ239558A (en) 1993-10-26

Similar Documents

Publication Publication Date Title
CA2090404A1 (en) Nonaqueous fluorinated drug delivery vehicle suspensions
EP2186902A3 (en) Medical preparations for the treatment of alpha-galactosidase a deficiency
AU608264B2 (en) Delivery vehicles with amphiphile-associated active ingredient
CA2046830A1 (en) Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
CA2439500A1 (en) Drug delivery system for hydrophobic drugs
CA2278541A1 (en) Pharmaceutical preparations and methods for their regional administration
MX9601591A (en) Thermally-gelling ophthalmic drug delivery vehicles containing cellulose ethers.
CA2386690A1 (en) Pharmaceutical tramadol salts
ATA333087A (en) PHARMACEUTICAL PREPARATION FOR THE INTRAVENOUS ACTIVE SUBSTANCE APPLICATION WITH HYDROSOLS IN THE NANOMETER AREA
AU2800689A (en) Differential delivery of therapeutic agents across the blood brain barrier
IT8920898A0 (en) USE OF WET SUCRALFATE GEL FOR THE TREATMENT OF DERMIC ULCERS AND AS A VEHICLE FOR TOPICAL ACTIVE DRUGS.
ATE191845T1 (en) PHARMACEUTICAL CARRIER FOR TOPICAL OPHTHALMIC USE
EP0147185A3 (en) Therapeutic use of cytidyl disphosphocholine to increase neuronal acetylcholine
MY110074A (en) Pharmacuetical formulation.
FR2572932B1 (en) INSOLUBLE DRUG LOCALLY ADMINISTERED IN THE EAR
ITRM930034A0 (en) ACTIVE AGENT TO REDUCE THE BLOOD LEVEL OF GLUCOCORTICOIDS AND PREVENT BRAIN DISORDERS DUE TO STRESS AND SENILITY.
CA2035492A1 (en) Liquid lavage/ventilation of the pulmonary system
JPS6461429A (en) Remedy for cancer
Goosby et al. Medical care of HIV disease in methadone maintenance treatment
RU98106825A (en) MEANS FOR TREATMENT OF HERPETIC DISEASES OF THE EYES
Slusarek et al. Toxicity of Fobos M-2 preparation. Part II. Effect of the preparation on the skin.
AU2065488A (en) The preparation of antigens of human immunodeficiency virus type 1, and the use thereof as diagnostic and therapeutic agent
Bottorff Breastmilk, the emic perspective of mothers
品田章二 Appropriate platelet transfusion therapy.
Sklyut et al. Vestibular dysfunction in clinical picture of acute alcoholic intoxication.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed